e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Therapeutic approaches in inflammatory lung disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Investigating the role of cathepsin S in the pathogenesis of cystic fibrosis-like lung disease
Ryan Brown (Belfast, United Kingdom), Ryan Brown, Donna Small, Anthony Abladey, Leslie Holsinger, Robert Booth, Chris Scott, Stuart Elborn, Marcus Mall, Sinéad Weldon, Cliff Taggart
Source:
International Congress 2015 – Therapeutic approaches in inflammatory lung disease
Session:
Therapeutic approaches in inflammatory lung disease
Session type:
Thematic Poster Session
Number:
3903
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Ryan Brown (Belfast, United Kingdom), Ryan Brown, Donna Small, Anthony Abladey, Leslie Holsinger, Robert Booth, Chris Scott, Stuart Elborn, Marcus Mall, Sinéad Weldon, Cliff Taggart. Investigating the role of cathepsin S in the pathogenesis of cystic fibrosis-like lung disease. Eur Respir J 2015; 46: Suppl. 59, 3903
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
A role for cathepsin S in the pathogenesis of cystic fibrosis lung disease?
Source: Annual Congress 2011 - Cell biology of lung disease
Year: 2011
The immunomodulatory effect of protein S in pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Specialized-proresolving mediators and trancriptomic signatures in bleomycin-induced lung fibrosis
Source: International Congress 2016 – Common mechanisms in lung development and fibrosis
Year: 2016
The role of
CFTR/ENaC
genotype in cystic fibrosis-like phenotypes
Source: International Congress 2014 – Cystic fibrosis: basic science, physiology and clinical aspects
Year: 2014
Genetics, pathophysiology and diagnosis of Cystic fibrosis
Source: ERS Skills Course 2016
Year: 2016
MiR-214-3p, a new fibromiR involved in the pathogenesis of idiopathic pulmonary fibrosis
Source: International Congress 2014 – Pathogenetic mechanisms in pulmonary fibrosis
Year: 2014
Increased systemic inflammation in cystic fibrosis (CF) is associated with deterioration in lung clearance index (LCI)
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014
Regulation of interleukin-8 by miR-17 during chronic inflammation in cystic fibrosis
Source: International Congress 2015 – The multiple faces of host defense
Year: 2015
New insights into the pathophysiology of lung disease in cystic fibrosis patients
Source: ISSN=ISSN 1025-448x, ISBN=ISBN 1-904097-46-6, page=1
Year: 2006
Pathophysiology of cystic fibrosis lung disease
Source: Eur Respir Monogr 2014; 64: 1-13
Year: 2014
Matrix metalloproteinase-2 is protective in bleomycin-induced pulmonary fibrosis
Source: International Congress 2015 – Animal studies of asthma and other inflammatory conditions
Year: 2015
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Cystic fibrosis lung disease assessed by lung clearance index
Source: Annual Congress 2013 –Cystic fibrosis: physiotherapy, exercise and lung function in adults and children
Year: 2013
Dissecting the role of TRPC6-channels in bleomycin-induced pulmonary fibrosis
Source: International Congress 2014 – ILDs 3
Year: 2014
Interaction between mitochondrial ROS and ER stress on PHMG-induced pulmonary fibrosis
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Nintedanib reduces bleomycin-induced lung inflammation and fibrosis in mice
Source: Annual Congress 2013 –Preclinical models for the development of new drugs for respiratory diseases
Year: 2013
Role of dendritic cells in pulmonary fibrosis in mice
Source: International Congress 2016 – ILD: from the bench to the bedside
Year: 2016
Comparison of expression of napsin A and surfactant protein D in bleomycin-induced pulmonary fibrosis mouse model
Source: Annual Congress 2013 –Diffuse parenchymal lung disease I
Year: 2013
Targeting of cathepsin S reduces cystic fibrosis-like lung disease
Source: Eur Respir J, 53 (3) 1801523; 10.1183/13993003.01523-2018
Year: 2019
Polymorphisms in
NOS-1
and
NOS-3
genes may influence the cystic fibrosis severity?
Source: International Congress 2014 – Cystic fibrosis: genotypes, inflammation and microbiology
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept